Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Fineline Cube Aug 17, 2026
Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Fineline Cube Aug 17, 2026
Company

Insilico Medicine Opens AI Biotech Research Center in Abu Dhabi

Fineline Cube Feb 6, 2023

China-based AI-powered drug discovery firm Insilico Medicine has revealed the opening of an AI-powered biotechnology...

Digital Medical Device

Vertex’s MoDAS System Gains NMPA Approval for Movement Disorder Assessment

Fineline Cube Feb 6, 2023

China-based Vertex has announced receiving medical device approval from the National Medical Products Administration (NMPA)...

Company Digital

BeiGene Launches Mental Health Program for Cancer Patients

Fineline Cube Feb 6, 2023

China-based biotech BeiGene (Nasdaq: BGNE; HKG: 6160; SHA: 688235) has announced the launch of a...

Company Deals

AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics

Fineline Cube Feb 6, 2023

Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have...

Company Drug

Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment

Fineline Cube Feb 6, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND)...

Company Deals

Forlong Biotechnology Secures Series A Funding for Protein Drug Development

Fineline Cube Feb 6, 2023

Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards...

Company Deals

Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06

Fineline Cube Feb 6, 2023

Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK...

Company Deals

Haisco Pharmaceutical Announces Public Offering for Clinical Studies

Fineline Cube Feb 6, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering...

Company Drug

BDgene’s CRISPR-Cas9 Therapy BD111 Accepted for CDE Review

Fineline Cube Feb 6, 2023

Shanghai BDgene Technology Co., Ltd has announced that a clinical trial filing for its BD111,...

Company Drug

JunTop Biosciences’ COVID-19 Therapy Mindewei Priced at RMB 795 per Course

Fineline Cube Feb 6, 2023

Sichuan’s provincial Healthcare Security Administration bureau has notified that Shanghai JunTop Biosciences Co., Ltd’s COVID-19...

Company Deals

Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440

Fineline Cube Feb 6, 2023

Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...

Company Drug

Mabwell’s Novel ADC 9MW2921 Accepted for NMPA Review

Fineline Cube Feb 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...

Company

Amgen Reports Q4 and Full-Year 2022 Financials with Global Sales Growth

Fineline Cube Feb 6, 2023

US major Amgen (NASDAQ: AMGN) has released its Q4 and full-year 2022 financials. Global sales...

Company

GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift

Fineline Cube Feb 6, 2023

UK-based GlaxoSmithKline plc (NYSE: GSK) has released its financial report for Q4 and the full-year...

Policy / Regulatory

China’s NMPA Releases 64th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Feb 3, 2023

China’s National Medical Products Administration (NMPA) has released the 64th batch of reference drugs for...

Company Drug

Bristol-Myers Squibb’s Ozanimod Approved in China for Multiple Sclerosis

Fineline Cube Feb 3, 2023

Bristol-Myers Squibb (BMS, NYSE: BMY) has announced receiving marketing approval from China’s National Medical Products...

Company

Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales

Fineline Cube Feb 3, 2023

Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF...

Company

Merck & Co. Posts 22% YOY Sales Growth; Keytruda and Gardasil Drive Revenues

Fineline Cube Feb 3, 2023

Merck & Co. (NYSE: MRK) has released its Q4 and full-year 2022 financial report, showcasing...

Company

Takeda Posts Strong Q3 Results, Announces Pipeline Advances in Oncology and Rare Diseases

Fineline Cube Feb 3, 2023

Japan-based pharmaceutical giant Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...

Company Drug

GenScript’s CAR-T Therapy Carvykti Achieves $55M in Sales, Awaits China Approval

Fineline Cube Feb 3, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that sales of...

Posts pagination

1 … 609 610 611 … 709

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
  • CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma
  • Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets
  • Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.